MBX Biosciences names chief scientific officer
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
Carmel-based clinical stage biopharmaceutical company MBX Biosciences Inc. has selected Steven Prestrelski as chief scientific officer. Prestrelski most recently served as founder and CSO of Xeris Biopharma Holdings Inc. in Chicago.
MBX is developing what are known as Precision Endocrine Peptide, or PEP, therapeutics to treat various endocrine disorders.
The company said Prestrelski has more than 30 years of expertise in leading endocrine and metabolism product development programs from discovery to regulatory approval.
“He has an impressive track record in building and operating impactful scientific organizations, and I am confident he will strengthen our entire research team and favorably position the company for future growth,” CEO Kent Hawryluk said in a news release. “We look forward to Steve’s contributions during this pivotal time for our peptide development programs.”
MBX said former CSO Richard DiMarchi will transition to the role of consulting scientific advisor, principal investigator and member of the company’s board of directors.
In the transition, DiMarchi will focus on “designing transformative molecules and expanding the MBX platform technology through sponsored research at Indiana University,” the company said.
Last year, MBX closed on $115 million in funding that it said would help get its lead drug, MBX 2109, through early- and mid-stage clinical trials, our partners at the IBJ reported. The drug is in development for treatment of hypoparathyroidism.